![]() ![]() ![]() Monitoring more individuals remotely will also help to lessen the spread of COVID-19. HCQ use sometimes carries dangerous and life-threatening side-effects such as drug-induced sudden cardiac death, according to the CDC.īecause the CAM can be worn on patients and tracked remotely, this means patients can be monitored while in the comfort of their own home, and hospital settings benefit from increased space. residents were recently experimentally given hydroxychloroquine (HCQ) to treat COVID-19 symptoms. These devices have also seen an increase in prescription as some U.S. Longer monitoring periods provide healthcare providers with the opportunity to potentially detect infrequent arrhythmias that may go unnoticed during a shorter period of time.ĬAM patches are now increasingly being prescribed for home use, as hospital space has become limited. ![]() The patches allow for a longer period of monitoring than previous products, that were used for 2 or 7-day periods. hospital settings, but they have now been granted a CE mark for these products. ![]() Image courtesy of Bardy Diagnostics.īardy Diagnostics‘ 14-day Carnation Ambulatory Monitor (CAM) patches have previously been used in U.S. Bardy is seeking favorable judgment, preliminary and permanent injunctive relief, damages, litigation fees, prejudgment interest, a trial by jury, and more.The plaintiff is represented by Potter Anderson & Corroon LLP and Riley Safer Holmes & Cancila LLP.The Carnation Ambulatory Monitor patch can monitor patients for up to 14 days. The complaint cites one count of infringement in regard to the ‘743 patent. The complaint asserts that the defendant’s VitalPatch meets every claim of the ‘743 patent, meaning that the defendant has “indirectly infringed” on the patent-in-suit by “actively and knowingly inducing patients to use the VitalPatch.” The defendant has allegedly been aware of their purported infringement since the filing of the Complaint. VitalPatch is a wearable device intended to collect data regarding a patients “heart rate, electrocardiographic signals, respiratory rate, body temperature, skin temperature, and activity such as step count.” The defendant’s product, VitalPatch, is said to include a Bluetooth transmitter. The ‘743 patent claims the CAM patch as an electrocardiography monitor with Bluetooth abilities and the ability to capture and store electrocardiographic signals. 11,051,743 (the ‘743 patent), which was issued in mid-2021.īardy alleges that the defendant, VitalConnect, is infringing on the aforementioned patent by manufacturing and marketing their product under the names “VitalPatch or VitalConnect Sensor, including without limitation the VitalPatch Biosensor, VitalPatch 1.0, VitalPatch1.5, VitalPatch 2.0, VitalPatch RTM, and/or any other versions thereof.” The suit comes following allegations that the defendant infringed on the plaintiff’s patents when they began manufacturing and marketing their VitalPatch product.īardy is the “developer of an industry leading electrocardiography monitor called the CAM patch.” The rights, title, and interest of the monitor is protected by U.S. Friday saw the filing of a complaint in the District of Delaware by Bardy Diagnostics, Inc. ![]()
0 Comments
Leave a Reply. |